Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20874
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartin-Algarra, Salvador-
dc.contributor.authorHinshelwood, Rebecca-
dc.contributor.authorMesnage, Soizick-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorFerrucci, Pier Francesco-
dc.contributor.authorAglietta, Massimo-
dc.contributor.authorNeyns, Bart-
dc.contributor.authorChiarion-Sileni, Vanna-
dc.contributor.authorLindsay, Colin R-
dc.contributor.authorDel Vecchio, Michele-
dc.contributor.authorLinardou, Helen-
dc.contributor.authorMerelli, Barbara-
dc.contributor.authorTonini, Giuseppe-
dc.contributor.authorAtkinson, Victoria-
dc.contributor.authorFreivogel, Klaus-
dc.contributor.authorStein, Dara-
dc.contributor.authorDalland, Lindi-
dc.contributor.authorLau, Mike-
dc.contributor.authorLegenne, Philippe-
dc.contributor.authorQueirolo, Paola-
dc.contributor.authorMillward, Michael-
dc.date2019-05-14-
dc.date.accessioned2019-06-05T01:28:44Z-
dc.date.available2019-06-05T01:28:44Z-
dc.date.issued2019-10-
dc.identifier.citationMelanoma research 2019; 29(5): 527-532-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20874-
dc.description.abstractGiven the approval of dabrafenib in patients with BRAF-mutant metastatic melanoma, a better understanding of treatment patterns and clinical outcomes with dabrafenib in a clinical setting is warranted. We performed a retrospective chart review of patients who received dabrafenib in a compassionate use setting through the Named Patient Program (DESCRIBE I study) during December 2010-August 2013 in Europe, New Zealand and Australia. Of the 331 Named Patient Program patients included, the majority (95.8%) had stage IV disease at dabrafenib initiation and 39.9% had brain metastases (BMs). Dabrafenib was used first line in 67.7% of patients, and median treatment duration was 6.4 months. Dabrafenib was well tolerated. Common grade 2/3 adverse events were hyperkeratosis (7.6%), pyrexia/fever (6.6%), fatigue (5.1%), hand-foot syndrome (5.4%) and nausea (3.6%). Overall response rate was 45.9%, median progression-free survival was 5.2 months (95% confidence interval, 4.2-6.1 months), and median overall survival was 12.4 months (95% confidence interval, 10.2-15.0 months). In patients with known brain metastases (n = 132) versus patients without (n = 199), overall response rate was 42.4% versus 48.2%, progression-free survival was 3.9 months (95% confidence interval, 3.8-5.5 months) versus 5.9 months (95% confidence interval, 4.8-7.8 months) and overall survival was 9.5 months (95% confidence interval, 6.7-12.4 months) versus 15 months (95% confidence interval, 11.1-20.5 months), respectively. Safety and effectiveness of dabrafenib in patients with unresectable advanced BRAF V600-mutant melanoma treated in an Named Patient Program was similar to the clinical trial experience, demonstrating effectiveness of dabrafenib in a nontrial setting.-
dc.language.isoeng-
dc.titleEffectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.-
dc.typeJournal Article-
dc.identifier.journaltitleMelanoma research-
dc.identifier.affiliationDepartment of Medical Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain-
dc.identifier.affiliationSchool of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australiaen
dc.identifier.affiliationMelanoma Unit, European Institute of Oncology, Milano, Italyen
dc.identifier.affiliationAuckland City Hospital, Auckland, New Zealanden
dc.identifier.affiliationGallipoli Medical Research Foundation, University of Queensland and Princess Alexandra Hospital, Brisbane, QLD, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationBeatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, and Institute of Cancer Sciences, University of Glasgow, Glasgow, UKen
dc.identifier.affiliationDepartment of Medical Oncology, Candiolo Cancer Institute, University of Torino, Torino, Italy-
dc.identifier.affiliationDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium-
dc.identifier.affiliationMelanoma and Esophageal Cancer Unit, Istituto Oncologico Veneto, Istituto Di Ricovero e Cura a Carattere Scientifico, Padova, Italy-
dc.identifier.affiliationDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy-
dc.identifier.affiliationFirst Department of Oncology, Metropolitan Hospital, Athens, Greece-
dc.identifier.affiliationDepartment of Medical Oncology, ASST Papa Giovanni XXIII, Bergamo-
dc.identifier.affiliationDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy-
dc.identifier.affiliationUBC, Lörrach, Germany-
dc.identifier.affiliationUBC, Montreal, QC, Canada-
dc.identifier.affiliationNovartis Norge AS, Oslo, Norway-
dc.identifier.affiliationNovartis Pharma AG, Basel, Switzerland-
dc.identifier.affiliationUOC Oncologia Medica, IRCCS San Martino-IST, Genova, Italy-
dc.identifier.doi10.1097/CMR.0000000000000608-
dc.identifier.orcid0000-0002-3898-950X-
dc.identifier.pubmedid31095039-
dc.type.austinJournal Article-
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.